Around a quarter of new amyloidosis patients die within 6 months of diagnosis, and, despite large pharmacological and technological advancements, this statistic has not improved over the past three decades. Here, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, highlights two of the primary requirements of future amyloidosis research in order to reduce this mortality rate. Dr Wechalekar emphasizes the need to improve awareness of the disease in primary care settings to increase the speed of diagnosis. This video was recorded at the Myeloma 2017 meeting in Edinburgh, UK.
An unmet need: reducing early death in amyloidosis
